Peter R Sinnaeve
Overview
Explore the profile of Peter R Sinnaeve including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
77
Citations
1043
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bainey K, Welsh R, Zheng Y, Arias-Mendoza A, Ristic A, Averkov O, et al.
Circ Cardiovasc Interv
. 2024 Dec;
17(12):e014251.
PMID: 39689189
Background: In STREAM-1 (Strategic Reperfusion Early After Myocardial Infarction), excess intracranial hemorrhage occurred in patients aged ≥75 years receiving full-dose tenecteplase as part of a pharmaco-invasive strategy, whereas no further...
2.
Sinnaeve P, Welsh R, Arias Mendoza A, Ristic A, Averkov O, Lambert Y, et al.
Circulation
. 2024 Sep;
150(14):1151-1153.
PMID: 39348454
No abstract available.
3.
Abtan J, Bhatt D, Elbez Y, Ducrocq G, Goto S, Smith Jr S, et al.
Int J Cardiol
. 2022 Oct;
370:51-57.
PMID: 36270493
Aims: THEMIS is a double-blind, randomized trial of 19,220 patients with diabetes mellitus and stable coronary artery disease (CAD) comparing ticagrelor to placebo, in addition to aspirin. The present study...
4.
Gevaert S, Halvorsen S, Sinnaeve P, Sambola A, Gulati G, Lancellotti P, et al.
Eur Heart J Acute Cardiovasc Care
. 2022 Oct;
11(11):865-874.
PMID: 36226746
Advances in treatment, common cardiovascular (CV) risk factors and the ageing of the population have led to an increasing number of cancer patients presenting with acute CV diseases. These events...
5.
Life-threatening paraneoplastic cardiovascular events in ALK-positive anaplastic large cell lymphoma
Verhaeghe C, Meijers B, Mertens A, Sinnaeve P, Jentjens S, Baten A, et al.
Ann Hematol
. 2021 Sep;
100(11):2851-2853.
PMID: 34586462
No abstract available.
6.
Valgimigli M, Storey R, Sinnaeve P, Riederer M, Bernaud C, Frenoux J
J Cardiovasc Pharmacol
. 2021 Sep;
79(2):153-154.
PMID: 34475343
No abstract available.
7.
Veltman D, Wu M, Pokreisz P, Claus P, Gillijns H, Caluwe E, et al.
JACC Basic Transl Sci
. 2021 Sep;
6(8):631-646.
PMID: 34466750
The bacterial C-type lectin domain family 4 member E (CLEC4E) has an important role in sterile inflammation, but its role in myocardial repair is unknown. Using complementary approaches in porcine,...
8.
Gevaert S, Halvorsen S, Sinnaeve P, Sambola A, Gulati G, Lancellotti P, et al.
Eur Heart J Acute Cardiovasc Care
. 2021 Aug;
10(8):947-959.
PMID: 34453829
Advances in treatment, common cardiovascular (CV) risk factors and the ageing of the population have led to an increasing number of cancer patients presenting with acute CV diseases. These events...
9.
Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol
Schwartz G, Szarek M, Bittner V, Diaz R, Goodman S, Jukema J, et al.
J Am Coll Cardiol
. 2021 Jul;
78(5):421-433.
PMID: 34325831
Background: Guidelines recommend nonstatin lipid-lowering agents in patients at very high risk for major adverse cardiovascular events (MACE) if low-density lipoprotein cholesterol (LDL-C) remains ≥70 mg/dL on maximum tolerated statin...
10.
Sinnaeve P, Adriaenssens T
Am J Cardiol
. 2021 Mar;
144 Suppl 1:S23-S31.
PMID: 33706987
Dual antiplatelet therapy (DAPT), the combination of aspirin (ASA), and a P2Y inhibitor, protects against stent thrombosis and new atherothrombotic events after a stent implantation or an acute coronary syndrome,...